Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, MD, Victor S. Blanchette, MD FRCP, Jenny M. Despotovic, DO, MS, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, DO, Kun Nie, Melissa Eisen, MD

Blood (2015) 126 (23): 3467.

https://doi.org/10.1182/blood.V126.23.3467.3467

Published: 2015

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

Journal Articles

KLF1 -null neonates display hydrops fetalis and a deranged erythroid transcriptome

Graham W. Magor, Michael R. Tallack, Kevin R. Gillinder, Charles C. Bell, Naomi McCallum, Bronwyn Williams, Andrew C. Perkins

Blood (2015) 125 (15): 2405–2417.

https://doi.org/10.1182/blood-2014-08-590968

Published: 2015

Includes: Supplemental data

Journal Articles

KLF1 Null Neonates Display Hydrops Fetalis and a Deranged Erythroid Transcriptome

Andrew C Perkins, MDPhD, Graham Magor, BSc, Michael R Tallack, BSc PhD, Kevin R Gillinder, BSc PhD, Charles Bell, BSc, Bronwyn Williams, MBBS,FRACP,FRCPA

Blood (2014) 124 (21): 2700.

https://doi.org/10.1182/blood.V124.21.2700.2700

Published: 2014

Journal Articles

Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin

Jenny Chia, Kevin Thia, Amelia J. Brennan, Margaret Little, Bronwyn Williams, Jamie A. Lopez, Joseph A. Trapani, Ilia Voskoboinik

Blood (2012) 119 (7): 1713–1716.

https://doi.org/10.1182/blood-2011-08-374355

Published: 2012

Includes: Supplemental data

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Steven W. Lane, Russell Saal, Peter Mollee, Andrew Grigg, Kerry Taylor, John Francis Seymour, Glen Kennedy, Bronwyn Williams, Mark Jones, Karen Grimmett, Vanessa Griffiths, Devinder Gill, Matthew Hourigan, Paula Marlton

Blood (2006) 108 (11): 2296.

https://doi.org/10.1182/blood.V108.11.2296.2296

Published: 2006

NARROW

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

KLF1 -null neonates display hydrops fetalis and a deranged erythroid transcriptome

KLF1 Null Neonates Display Hydrops Fetalis and a Deranged Erythroid Transcriptome

Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

KLF1 -null neonates display hydrops fetalis and a deranged erythroid transcriptome

KLF1 Null Neonates Display Hydrops Fetalis and a Deranged Erythroid Transcriptome

Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only